Antiarrhythmic versus control: study Included in the Systematic review
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2009 Feb 12;360(7):668-78 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009 The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 21 months cardiovascular deaths (2.7% dronedarone VS 3.9% placebo) and hospitalizations (26.9% dronedarone VS 33.4% placebo). No significant difference in overall mortality.
J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605 Study type to be defined
IN atrial fibrillation, recent-onset, persistent, StudyID: DYONISOS 2010 The Use of
dronedarone
As Treatment, Chronic
Is worse Than
amiodarone
To reduce, at 6 months, AF recurrence. Dronedarone had slightly fewer deaths and adverse events but differences were not significants
Am Heart J. 2006 May;151(5):1043-9 Randomized Controlled Trial
IN StudyID: A-COMET-I 2006, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To maintain sinus rhythm or modify death at 6 months. Azimilide caused more adverse events and pro-arrhythmia
Eur Heart J. 2006 Sep;27(18):2224-31. Epub 2006 Aug 25 Randomized Controlled Trial
IN StudyID: A-COMET-II 2006, atrial fibrillation The Use of
azimilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To prevent, at 6 months, AF recurrence without being stopped because adverse effects: sotalol 33% VS 19% azim VS 15% placebo. Both azimilide and sotalol increased proarrhythmia.
Circulation. 1997 Oct 21;96(8):2625-32 Randomized Controlled Trial, Multicenter Trial
IN StudyID: AFIB 1997, atrial fibrillation The Use of
bidisomide
As Treatment, Chronic
Is equal Than
placebo
To AF recurrence, mortality - at ? Time
Am J Cardiol. 2001 Nov 1;88(9):974-9 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, pro-arrhythmia - at 6 months
Am Heart J. 2002 Apr;143(4):643-9 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
J Am Coll Cardiol. 2000 Sep;36(3):794-802 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence - at ? Time
Am Heart J. 2003 Sep;146(3):489-93 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To symptoms at AF recurrence, adverse effects - at 6 months
Circulation. 2003 Mar 4;107(8):1141-5 Randomized Controlled Trial
IN StudyID: ASAP 2003, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
Am J Cardiol. 2006 Jul 15;98(2):215-8 Randomized Controlled Trial
IN StudyID: A-START 2006, atrial fibrillation, paroxysmal or recent-onset The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To modify time to AF recurrence. Azimilide increased adverse effects and pro-arrhytmia. No deats were reported
Am J Cardiol. 1999 Aug 1;84(3):270-7 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Benditt 1999, atrial fibrillation The Use of
sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, mortality, adverse effects - at 12 months
Br Heart J 1970 May;32(3):370-6 Randomized Controlled Trial
IN StudyID: Byrne-Quinn 1970, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia, mortality - at 12 months
Eur Heart J. 2004 Jan;25(2):144-50 Randomized Controlled Trial
IN StudyID: Channer 2004, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 12 months
Eur Heart J. 2003 Aug;24(16):1481-7 Randomized Controlled Trial
IN StudyID: DAFNE 2003, atrial fibrillation, persistent The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Am Heart J. 2008 Aug;156(2):373.e1-8 Randomized Controlled Trial
IN StudyID: DAPHNE 2008, atrial fibrillation, paroxysmal, sinus node disease The Use of
sotalol
As Treatment, Chronic
Is equal Than
beta-blockers, atenolol, metoprolol
To reduce AF recurrences
Ugeskr Laeger. 2000 Oct 30;162 (44);5948-53 Randomized Controlled Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 1 year
Congest Heart Fail. 2001 May-Jun;7(3):146-150 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization because heart failure, adverse effects, proarythmia - at 12 months
N Engl J Med. 1999 Sep 16;341(12):857-65 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001 (subordinated publication), atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 18 months
Circulation. 2001 Jul 17;104(3):292-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: DIAMOND 2001, atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To mortality, FA recurrence, rehospitalization, heart failure - at 12 months
Acta Cardiol. 2004 Jun;59(3):255-61 Randomized Controlled Trial
IN StudyID: Dogan 2004, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To at 15 months: AF recurrence, adverse effects
J Cardiovasc Pharmacol Ther. 2003 Sep;8(3):179-86 Clinical Trial (non-controlled, non-randomized)
IN StudyID: GEFACA 2001 (subordinated publication), atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is - Than
no comparison
To AF recurrence, adverse effects - at > 12 months
J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):341-50 Randomized Controlled Trial, Multicenter Trial
IN StudyID: GEFACA 2001, atrial fibrillation, persistent The Use of
amiodarone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at average 9 months
Br Heart J 1971 Jul;33(4):518-21 Controlled Clinical Trial
IN StudyID: Hillestad 1971, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is better Than
no treatment
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia, mortality - at 12 months
Lakartidningen. 1991 Jun 12;88(24):2242-5 Randomized Controlled Trial
IN StudyID: Karlson 1988 (subordinated publication), atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is better Than
placebo
To not available
Eur Heart J. 1988 Mar;9(3):284-90 Randomized Controlled Trial
IN StudyID: Karlson 1988, atrial fibrillation The Use of
disopyramide
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, stroke, mortality - at 12 months
J Am Coll Cardiol. 2000 Jul;36(1):139-46 Randomized Controlled Trial
IN StudyID: Kuhlkamp 2000, atrial fibrillation, persistent The Use of
beta blockers, metoprolol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
Eur Heart J. 2007 Jun;28(11):1351-7 Randomized Controlled Trial
IN StudyID: Nergardh 2007, atrial fibrillation The Use of
beta blockers, metoprolol, plus repeated cardioversion if needed
As Treatment, Chronic
Is better Than
placebo, plus repated cardioversion if needed
To reduce recurrence of AF at 6 months: 54% metoprolol VS 74% placebo.
Am Heart J. 2000 Sep;140(3):437-44 Randomized Controlled Trial
IN StudyID: Okishige 2000, atrial fibrillation, persistent The Use of
pilsicainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, mortality, adverse effects - at 12 and 24 months
Am J Cardiol. 2003 Oct 15;92(8):941-6 Randomized Controlled Trial
IN StudyID: RAFT 2003, atrial fibrillation The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at ? Time
Circulation. 2000 Nov 7;102(19):2385-90 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SAFIRE 2000, atrial fibrillation, persistent The Use of
dofetilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, proarrhythmia - at 12 months
Am J Cardiol. 1991 Nov 1;68(11):1227-30 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Singh 1991, atrial fibrillation, persistent The Use of
sotalol
As unknow
Is - Than
unknow
To unknow
Circ J. 2002 Jun;66(6):553-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: SMART 2002, atrial fibrillation The Use of
aprindine
As Treatment, Chronic
Is equal Than
digoxin, placebo
To AF recurrence, adverse effects - at 6 months
Br Heart J 1975 May;37(5):486-92 Randomized Controlled Trial
IN StudyID: Sodermark 1975, atrial fibrillation The Use of
quinidine
As Treatment, Chronic
Is better Than
no treatment
To AF recurrence, adverse effects - at 12 months
Am J Cardiol. 1997 Feb 15;79(4):418-23 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Stroobandt 1997, atrial fibrillation, persistent The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
J Cardiovasc Electrophysiol. 2008 Feb;19(2):172-7 Randomized Controlled Trial
IN StudyID: SVA-4, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To modify, at 6 months, mortality or Af recurrence, while increasing adverse effects and pro-arrhythmia
Circulation (Supp) 1988;78(4):ii626 Randomized Controlled Trial
IN StudyID: Van Gelder 1989 (subordinated publication), atrial fibrillation, persistent The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To not available
Am J Cardiol. 1989 Dec 1;64(19):1317-21 Randomized Controlled Trial
IN StudyID: Van Gelder 1989, atrial fibrillation, persistent The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, proarrhythmia - at ? time